Tessera
Folgen

Elaine Chen

@elaineywchen.bsky.social

Reporter @statnews.com covering drugs and the biopharma industry | signal: elaineywchen.70

51 Posts2720 Follower126 Folgt
Elaine Chen@elaineywchen.bsky.social · last yr.

Latest: A race to develop a new class of narcolepsy drugs could not only transform treatment for patients with the rare sleep disorder, but also many people with common health conditions like Alzheimer's and depression who struggle to stay awake

Drugmakers are racing to help patients stay awake — and could also make billions

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with other conditions that cause them to struggle to stay awake.

statnews.com

Elaine Chen@elaineywchen.bsky.social · last yr.

From #ADA25: Full results suggest Novo's CagriSema is comparable to Lilly’s Zepbound on safety and efficacy Weight loss looks to be plateauing at the end of late-stage studies, raising Qs around how much more weight patients can lose on the drug

Novo Nordisk’s amylin obesity drug keeps performing like Zepbound

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.

statnews.com

Elaine Chen@elaineywchen.bsky.social · last yr.

Latest from #ADA25: Novo's injectable amycretin showed substantial weight loss in an early study, but similar efficacy across different doses and high rates of side effects raise questions about which dose Novo will pursue going forward

Full data on Novo Nordisk’s new amylin drug raise dosing questions

Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, raising questions about which dose Novo will pursue.

statnews.com

Elaine Chen@elaineywchen.bsky.social · last yr.

LATEST: A conservative culture cost Novo Nordisk its lead in the obesity drug race, former employees told me It wanted to tread carefully as the first mover in the space, and its belief in Ozempic/Wegovy blinded it to other candidates, they said

A cautious culture cost Novo Nordisk its lead in the obesity drug race, former employees say

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say the company's cautious culture is to blame.

statnews.com

Isabella Cueto@isabellacueto.bsky.social · last yr.

NEW: How RFK Jr. goes about solving the chronic disease epidemic depends on his top concerns. Here, we break down the nation's health into 9 "priorities" — using original data analysis you can't find elsewhere! — and let you choose yours. W/ @jaspar.bsky.social: www.statnews.com/2025/05/20/k...

RFK Jr. declared war on chronic disease. First comes the battle over priorities

How would you solve the chronic disease epidemic? Here's STAT's extensive new data analysis, and nine ways to tackle the problem.

statnews.com

Elaine Chen@elaineywchen.bsky.social · last yr.

The explosion of compounded GLP-1 offerings is ending, and many patients are left with no good options. Telehealth companies and compounders are pursuing workarounds that may be riskier. At the same time, patients still can't afford the branded drugs. w/ @katiepalmer.bsky.social

The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from

statnews.com

Megan Molteni@mmolteni.bsky.social · last yr.

WaPo has the numbers on those NIH advisory board purges @jasonmast.bsky.social and I first reported on last month. Six percent of White males who serve on boards were fired, compared with half of Black and Hispanic females and one-quarter of all females, according to an analysis by board chairs.

The Washington Post@washingtonpost.com · last yr.

Thirty-eight of 43 experts cut last month from the boards that review the science and research that happens in laboratories at the National Institutes of Health are female, Black or Hispanic, according to an analysis by the chairs of a dozen of the boards.

Elaine Chen@elaineywchen.bsky.social · last yr.

RFK Jr. vowed to promote “radical transparency” at HHS. But today the dpt made major cuts to teams across its agencies that handle communications, media relations, and FOIA requests - w/ @lizzylawrence.bsky.social, @isabellacueto.bsky.social

After RFK Jr.’s ‘radical transparency’ pledge, HHS shutters much of its communications, FOIA operations

After health secretary RFK Jr.’s ‘radical transparency’ pledge, HHS has shuttered much of the agency's communications and FOIA operations.

statnews.com

Jason Ukman@jasonukman.bsky.social · last yr.

New: The NIH has canceled funding for a landmark diabetes study — at a time when RFK Jr. and the rest of the MAHA movement is focused on addressing chronic diseases, including diabetes. Smart story from @elaineywchen.bsky.social www.statnews.com/2025/03/17/t...

NIH cancels funding for landmark diabetes study at a time of focus on chronic disease

The Trump administration has canceled funding for an ongoing 30-year, nationwide study tracking patients with prediabetes and diabetes, researchers said.

statnews.com

Bob Herman@bobjherman.bsky.social · last yr.

Eli Lilly's obesity and diabetes drugs are paying off for top executives. CEO Dave Ricks took home $114 million last year, and he and other leaders also were treated to a "leadership meeting" at last summer’s Olympics in Paris. More w/ @elaineywchen.bsky.social: www.statnews.com/2025/03/11/e...

Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

statnews.com

Elaine Chen@elaineywchen.bsky.social · last yr.

NEW: Patients in trials of Lilly's next-gen obesity drug tell me they think they're losing too much weight. One started skipping doses, another is making himself eat caloric foods. This is part of what some see as a risky race for more weight loss www.statnews.com/2025/02/20/t...

How much weight loss is too much? Pharma is pushing the limit with new obesity drugs

How much weight loss is too much? Pharma is pushing the limit with new obesity drugs.

statnews.com